About Ardelyx, Inc.
https://www.ardelyx.comArdelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.
CEO
Michael G. Raab
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2021-07-20 | Forward | 4:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 114
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Citigroup
Buy
TD Cowen
Buy
Raymond James
Outperform
Wedbush
Outperform
Piper Sandler
Neutral
HC Wainwright & Co.
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:20.82M
Value:$143.47M
VANGUARD GROUP INC
Shares:18.37M
Value:$126.56M
BLACKROCK INC.
Shares:17.55M
Value:$120.94M
Summary
Showing Top 3 of 257
About Ardelyx, Inc.
https://www.ardelyx.comArdelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $110.33M ▲ | $104.34M ▲ | $-969K ▲ | -0.88% ▲ | $-0 ▲ | $5.83M ▲ |
| Q2-2025 | $97.66M ▲ | $99.65M ▲ | $-19.08M ▲ | -19.54% ▲ | $-0.08 ▲ | $-11.87M ▲ |
| Q1-2025 | $74.11M ▼ | $98.16M ▲ | $-41.14M ▼ | -55.51% ▼ | $-0.17 ▼ | $-33.42M ▼ |
| Q4-2024 | $116.13M ▲ | $89.74M ▲ | $4.64M ▲ | 4% ▲ | $0.02 ▲ | $11.05M ▲ |
| Q3-2024 | $98.24M | $80.28M | $-809K | -0.82% | $-0 | $5.06M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $242.71M ▲ | $486.17M ▲ | $331.89M ▲ | $154.28M ▲ |
| Q2-2025 | $238.45M ▲ | $466.77M ▲ | $327.24M ▲ | $139.53M ▼ |
| Q1-2025 | $213.95M ▼ | $410.19M ▼ | $264.52M ▲ | $145.68M ▼ |
| Q4-2024 | $250.1M ▲ | $435.75M ▲ | $262.46M ▲ | $173.29M ▲ |
| Q3-2024 | $190.4M | $367.86M | $209.57M | $158.3M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-969K ▲ | $365K ▲ | $-50.51M ▼ | $2.81M ▼ | $-47.33M ▼ | $209K ▲ |
| Q2-2025 | $-19.08M ▲ | $-25.34M ▲ | $34.92M ▲ | $49.66M ▲ | $59.24M ▲ | $-25.99M ▲ |
| Q1-2025 | $-41.14M ▼ | $-38.46M ▼ | $2.85M ▲ | $1.48M ▼ | $-34.12M ▼ | $-38.78M ▼ |
| Q4-2024 | $4.64M ▲ | $9.81M ▲ | $-41.62M ▼ | $49.31M ▲ | $17.5M ▲ | $9.22M ▲ |
| Q3-2024 | $-809K | $501K | $2.34M | $2.7M | $5.54M | $364K |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 Product | $110.00M ▲ | $110.00M ▲ | $90.00M ▼ | $70.00M ▼ |
 Product IBSRELA | $50.00M ▲ | $80.00M ▲ | $70.00M ▼ | $0 ▼ |
CEO
Michael G. Raab
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2021-07-20 | Forward | 4:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 114
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Citigroup
Buy
TD Cowen
Buy
Raymond James
Outperform
Wedbush
Outperform
Piper Sandler
Neutral
HC Wainwright & Co.
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:20.82M
Value:$143.47M
VANGUARD GROUP INC
Shares:18.37M
Value:$126.56M
BLACKROCK INC.
Shares:17.55M
Value:$120.94M
Summary
Showing Top 3 of 257